Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Outlook on the Worldwide Hepatitis C Drugs Industry to 2025 - Featuring Abbvie, Gilead Sciences, Merck & Co & Bristol-Myers Squibb Among Others

This is mainly caused by sharing needles, unsterilized medical equipment, and a blood transfusion from infected mothers to newborn babies. As per the research analysis, the Global Hepatitis C Drugs Market would be US$ 5.9 Billion by 2025.In recent years, several drugs have been launched due to the high prevalence of Hepatitis C across the globe. Mavyret has several advantages compared to other drugs such as its treatment course is shorter, and it is much cheaper. Harvoni drugs are popular in India, and it's easier affordable among the public.Oral injections and dosages are required weekly in Hepatitis C; at the same time, its side effects can lead to permanent damage of other organs of patients. The market share of Asia - Pacific's and Latin American regions will grow during the forecast period.The report titled Hepatitis C Drugs Market Global Forecast by Drugs (Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Abbvie, Gilead Sciences, Merck, Bristol-Myers Squibb, Others) provides a complete analysis Hepatitis C market globally.Mavyret is the leading drug in the global hepatitis C marketComplete analysis of 7 drugs Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others is given in the report.

First found on: And then on: 2 other references